Communication is not consistent when labeling does not enable safe and effective use as suggested

DisputedblockerFDA guidance · non-bindingRaised as a question — a person decides

Rule

One of the factors FDA considers is whether the directions for use in the FDA-required labeling enable the product to be safely and effectively used under the conditions represented or suggested in the product communication — including whether the labeling provides sufficient information about risks and effects, and appropriate context for any unique considerations raised by the suggested use. If the answer is no, that indicates the product communication is not consistent with the FDA-required labeling.

Check

For any use scenario depicted in the piece that is not explicitly in the label, check whether the label nonetheless gives enough risk/effect information, and appropriate context for any unique considerations raised by the suggested use, to safely and effectively use the product that way. A violation looks like a suggested use for which the label offers no meaningful safety or efficacy context.

Escalate when

Always — whether labeling provides 'sufficient' context is a judgment call requiring medical/regulatory review.

Where this comes from

Q.2/A.2, Factor 3 · page 9. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…e, if the representations or suggestions about use of the product would reasonably be expected to introduce new risks that are not included in the FDA-required labeling or to materially increase the rate of Contains Nonbinding Recommendations occurrence or severity of existing risks included in the FDA-required labeling, the communication would not be consistent with the FDA-required labeling. <u>Factor 3:</u> Whether the directions for use in the FDA-required labeling enable the product to be safely and effectively used under the conditions represented/suggested in the product communication — For example, when considering this question, firms should determine if the FDA-required labeling provides sufficient information about risks (i.e., information about the potential or expected risks) and effects of using the product as presented in the product communication. Similarly, firms should examine any unique considerations associated with the use of the product as suggested by the communication and assess w…

Open the original at page 9 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Basisconsistent-with-labeling

How this rule was checked

The verifier and drafter could not agree. Waiting for a human decision — not used in reviews.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The substance is established by the source, but not by the sentence stored as the quote. The stored quote is the illustrative sub-consideration ('For example, when considering this question, firms should determine if the FDA-required labeling provides sufficient information about risks ... and effects of using the product as presented in the product communication'). The proposition the rule actually states comes from the factor heading and its consequence: 'Factor 3: Whether the directions for use in the FDA-required labeling enable the product to be safely and effectively used under the conditions represented/suggested in the product communication' and 'If the answer to this question is no, that indicates the product communication is not consistent with the FDA-required labeling.' A rule shown as AI-verified should cite the operative sentence, not the example that follows it.
- The rule statement also narrows the factor. Factor 3 asks whether the labeling's directions for use enable safe and effective use under the represented conditions; the risks-and-effects sentence is only one thing firms are told to determine 'for example,' and the source adds a second: 'firms should examine any unique considerations associated with the use of the product as suggested by the communication and assess whether the FDA-required labeling furnishes the appropriate context.' Stating the rule purely as 'sufficient information about risks and effects' loses the directions-for-use core of the factor.
- Not overstated in force — the rule is framed as a consistency determination rather than an obligation, matching A.2 — though the title's 'Labeling must provide adequate directions' reads as an obligation on a nonbinding factor and also inverts the subject (the factor is about the communication's consistency, not a duty owed by the labeling).
- Atomic (one determination). 'Judgment' is correct and 'escalate always' is appropriate, since 'sufficient' and 'safely and effectively' are adequacy questions. 'Guidance' is correct, 'blocker' is defensible, and the locator 'Q.2/A.2, Factor 3' is right even though the chosen sentence within it is not. applies_when matches Q.2's 'product communication' framing, but note it differs from US-IND-007 through US-IND-010, which add a "promotional" limiter to the same framework.
- The Check is usable as written and correctly targets the case the source flags — a use scenario the labeling does not explicitly address.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The substance of the rule is supported: Q.2/A.2 Factor 3 asks 'Whether the directions for use in the FDA-required labeling enable the product to be safely and effectively used under the conditions represented/suggested in the product communication,' and the surrounding text tells firms to determine whether the labeling 'provides sufficient information about risks... and effects' and 'furnishes the appropriate context' for unique considerations — the elaborations in the rule statement are drawn from the source, not invented.
- The quote, however, is a referentially empty sentence: 'If the answer to this question is no...' drops the question it depends on, so a reader seeing only the quote cannot tell what is being asked. On its own it does not show what the rule requires.
- As quoted, the source says failing Factor 3 'indicates' the communication is not consistent, whereas the rule asserts flatly that it 'is not' consistent. The stronger formulation is available in the source (A.2: 'If a product communication fails to satisfy any one of these factors, it is not considered consistent with the FDA-required labeling'), but that sentence is not the one quoted, so as drafted the rule is stronger than its own quote.
- Atomic: a single consistency criterion, with the risk/effect and context language as elaborations of the one Factor 3 question rather than separate obligations.
- Determinism 'judgment' is correct — 'sufficient' information and 'appropriate' context are adequacy judgments. Authority 'guidance' matches the source document and the rule claims no more. The absence of a 'promotional' limit in applies_when is right: the three factors in Q.2/A.2 apply to product communications generally, not only to CFL promotional communications. Locator (Q.2/A.2, Factor 3) is correct.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The substance is supported. Q.2/A.2 Factor 3 asks whether the labeling's directions for use enable safe and effective use under the conditions the communication represents or suggests, and states: 'If the answer to this question is no, that indicates the product communication is not consistent with the FDA-required labeling.' The rule text faithfully includes the elaboration on sufficient risk/effect information and unique considerations, and it does not overstate. The title uses no 'must'.
- The quote is a heading fragment, not a sentence. It is the Factor 3 heading, with residual markup ('<u>Factor 3:</u>') and a trailing em dash, and it is phrased as a question ('Whether ...'). On its own it states no consequence, so it does not show that failing it makes the communication inconsistent. The operative sentence appears elsewhere in the source.
- Like Factor 2, this factor does not apply to 510(k)-cleared or 510(k)-exempt devices (Q.1/A.1: 'there is no need to separately analyze communications under the factors discussed in Q.2/A.2'). This is an obvious scope limit the vocabulary cannot express, so it belongs in the rule text.
- It is correctly marked judgment. Blocker severity is defensible because failing the factor removes the consistent-with-labeling basis. It is atomic.